Bispecific Antibodies Signal a New Era for Autoimmune Disease Treatment
(Posted on Tuesday, November 11, 2025)
|
|
|
|
A new approach targets the B-cell pathway with bispecific antibodies, building on decades of research that establishes the role of B cells and self-reactive antibodies in lupus, systemic sclerosis, and rheumatoid arthritis. While current therapies target B cells, bispecific antibodies are engineered proteins that connect T cells and B cells. This strategy provides results comparable to existing options, with greater flexibility and simpler administration. A recent report in the New England Journal of Medicine describes how the bispecific antibody teclistamab induces prolonged remission in patients who do not respond to other treatments. In some cases, a single course of therapy eliminates the need for daily medication for several months. Remission can last up to a year in select patients. Understanding Autoimmune DiseaseAutoimmune diseases such as systemic sclerosis, myositis, and rheumatoid arthritis affect millions worldwide. These conditions occur when the immune system attacks the body’s own tissues. In lupus, genetic and environmental factors disrupt immune tolerance, enabling B cells to produce autoantibodies that target normal cells. These immune complexes drive chronic inflammation, joint pain, fatigue, and organ dysfunction. Disrupting B-cell activity is a well-established strategy for managing autoimmune diseases. Standard therapies include rituximab, which removes specific B cells, and belimumab, which blocks B-lymphocyte stimulator to limit the survival of self-reactive B cells. Combined use of these drugs further suppresses abnormal immune responses and extends symptom relief. Many patients continue to depend on steroids or B-cell–targeted treatments, which often result in frequent relapses and significant side effects. For individuals who do not respond after multiple therapies, treatment options become limited. The Rise of Bispecific AntibodiesBispecific antibodies such as teclistamab introduce a new approach to autoimmune therapy. Unlike earlier methods that broadly deplete B cells, bispecific antibodies act with greater precision and specificity. Teclistamab binds to CD3 on T cells and B-cell maturation antigen on B cells and plasma cells. This mechanism brings T cells into contact with cells producing harmful antibodies, allowing selective elimination of these cells and resetting the immune system. |
|
|
|
|
This diagram illustrates how a bispecific antibody binds simultaneously to a T cell and a B cell. By connecting these two immune cells, the antibody directs the T cell to target and eliminate the problematic B cell, helping to regulate immune activity. Bispecific antibodies have demonstrated efficacy in blood cancers such as multiple myeloma and lymphomas, providing drug-free remissions. Early studies in autoimmune diseases, including lupus, systemic sclerosis, and rheumatoid arthritis, report that some patients achieve long-term remission after a single treatment, with extended periods without additional medication. The Results of a New TrialEarly data with teclistamab suggest that it may reset the immune system, extending beyond symptom control. Teclistamab is a bispecific T-cell engager that links T cells to B cells, including those producing harmful antibodies. This connection signals T cells to eliminate malfunctioning B cells, potentially restoring immune balance and reducing the need for ongoing immune suppression. Early clinical trials indicate that targeting B cells that produce autoantibodies results in rapid and durable remission, even in patients who are unresponsive to other treatments. Some individuals discontinue daily medications for months. Improvements in organ function and reductions in autoantibody levels suggest that the underlying disease may enter remission. Most patients experience mild, short-term side effects, including low-grade cytokine release syndrome, which causes fever or aches. Some develop minor, manageable infections. No severe neurological complications or life-threatening events are reported. Clinical trials for teclistamab in systemic sclerosis and rheumatoid arthritis are underway in Europe and the United States. These studies aim to determine the optimal dosing, duration of remission, and patient selection criteria. Long-term follow-up will assess the effects of repeat dosing and the potential for sustained health without ongoing treatment. How Does This Compare to Other Therapies?Bispecific antibodies differ from other immunotherapies, such as CAR T-cell therapy, which requires cell harvesting, genetic modification, reinfusion, and extended monitoring. This process is complex and costly. In contrast, bispecific antibodies like teclistamab are off-the-shelf medications that can be administered by subcutaneous injection in outpatient settings. Both CAR T and bispecific therapies reset the B-cell repertoire, achieving drug-free remissions. Bispecific antibodies offer a more straightforward, more accessible approach with comparable efficacy for some patients. Studies have shown that teclistamab rapidly reduces autoantibody levels and improves symptoms and organ function, without the need for chemotherapy or prolonged hospitalization. A key consideration in B-cell–targeted therapy is balancing disease control with preservation of immune function. Depleting autoreactive B cells reduces disease activity, but maintaining the ability to fight infections remains essential. Early data show that bispecific antibodies largely spare critical immune functions and have a manageable safety profile, with most side effects limited to mild cytokine release syndrome or treatable infections. Careful patient monitoring is necessary to prevent complications and optimize dosing. The Road Ahead: A New FrontierOngoing clinical trials in Europe and the United States will determine optimal use of bispecific antibodies, identify patients who benefit most, and assess strategies to extend remission while preserving immune health. These studies will provide critical insight and advance understanding of this emerging treatment. If future data confirm these early findings, bispecific antibodies may change the management of lupus and other severe autoimmune diseases. Sustained remission without lifelong medication may become achievable for patients who are unresponsive to standard therapies. This shift moves autoimmune medicine from broad immune suppression to precise, targeted strategies that address the underlying cause of immune dysfunction. Ultimately, bispecific therapies offer the potential to transform a field that has seen slow incremental progress for decades. For patients struggling with persistent symptoms despite standard care, these advances may offer renewed hope, supporting health, resilience, and quality of life without the need for continuous immune suppression. |
Read Dr. Haseltine's latest piece with
